A Year Into Turnaround, Novo CEO Says Investors Still Underestimate Drug Pipeline
As the GLP-1 market heats up, Novo Nordisk's chief insists Wall Street is missing the full value of its weight-loss and diabetes portfolio.
By Mohammed Al-Shehri·· 3 min